Rheumatoid Arthritis Patients & Abatacept Use

Last June at the annual European League Against Rheumatism (EULAR) scientific meeting in Madrid, the NDB presented some of the results from the RAlly study (the abatacept safety registry) and data from other rheumatoid arthritis (RA) patients in the data bank.

The research showed the characteristics of RA patients receiving abatacept without any prior biologic medication were older had more years of smoking, diabetes, cancer, high blood pressure and other medical problems. These patients also showed that they used less prednisone and methotrexate. When looking at RA patients who received abatacept as their 2nd biologic medication ever taken, the biologic they predominantly took first was infliximab. And then, when looking at RA patients who received abatacept as their 3rd biologic medication, their previous biologics tended to be etanercept, infliximab and adalimumab.

These characteristics will be important to take into consideration when future analysis comparing effectiveness of newer biologics is done.